RNA Therapy Clinical Trials Market | USD 4.16 Billion by 2034
The RNA therapy clinical trials market size was exhibited at USD 2.85 billion in 2024 and is projected to hit around USD 4.16 billion by 2034, growing at a CAGR of 3.85% during the forecast period 2024 to 2034.
| Report Coverage | Details |
| Market Size in 2025 | USD 2.96 Billion |
| Market Size by 2034 | USD 4.16 Billion |
| Growth Rate From 2024 to 2034 | CAGR of 3.85% |
| Base Year | 2024 |
| Forecast Period | 2024-2034 |
| Segments Covered | Modality, Clinical Trials Phase, Therapeutic Areas, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Covered | North America, Europe, Asia Pacific, Latin America, MEA |
| Key Companies Profiled | IQVIA; ICON Plc; Laboratory Corporation of America Holdings; Charles River Laboratories International, Inc.; PAREXEL International Corp.; Syneos Health; Medpace Holdings, Inc.; PPD Inc.; Novotech; Veristat, LLC. |
The market growth is majorly driven by the growing prevalence of genetic and rare diseases, a rise in R&D funding, the demand for novel therapies, and a favorable regulatory environment. Moreover, increasing RNA therapy approval is expected to drive market growth. Numerous oligonucleotide drugs are approved, and multiple is in phase III clinical trials, mainly for genetically well-defined rare disorders. The current bolus of investment in RNA therapeutics is likely to lead the future clinical success across multiple modalities and disease areas.
The success of RNA-based COVID-19 Vaccines is a major contributor to the RNA therapy clinical trial market. The development and widespread use of COVID-19 vaccinations based on mRNA by Pfizer-BioNTech and Moderna has successfully demonstrated the potential of RNA therapeutics on a worldwide scale. The safety and efficacy of mRNA-based technologies have been strongly demonstrated by the approval of mRNA vaccines. This approval has propelled confidence among regulatory bodies, researchers, and investors, encouraging further exploration of mRNA therapeutics in clinical trials.
Furthermore, the success of mRNA vaccines has led to significant attention from funding organizations and investors. The growing interest in mRNA therapies has attracted additional funding opportunities, enabling more research institutions and entities to carry out clinical trials in the arena. For instance, in April 2023, Sanofi announced that it will provide the MIT lab of Professor Daniel Anderson USD 25 million over a period of five years to support its research in creating messenger RNA delivery technology.
The increasing prevalence of genetic and rare diseases is expected to create opportunities for market growth in the coming years. According to the U.S. Department of Health & Human Services, over 10,000 known rare disorders that affect around 1 in 10 individuals (or 30 million individuals) in the U.S. Globally, an estimated 3.5 to 5.9% of people have a rare disease, many of which are RNDs, which are usually identified in childhood. mRNA technology enables the development of a broad range of therapeutic modalities including gene editing, protein replacement, and cancer immunotherapy. This versatility makes mRNA therapy a useful platform for addressing various rare diseases, resulting in boosting market growth.
On the other hand, increasing adoption of mRNA in cancer vaccines is also expected to boost the market growth in the forecast period. For the treatment of melanoma, colorectal, and pancreatic cancer using an mRNA vaccine, numerous clinical trials are now being conducted. mRNA cancer vaccines can be used as a personalized therapy or as a one-vaccine-to-many-people technique. Dendritic cells take the vaccine's mRNA and deliver it to T cells, directing them to search out and eliminate cancer cells.
Based on therapeutic areas, the market is divided into rare diseases, anti-infective, anticancer, neurological, musculoskeletal, alimentary/metabolic, cardiovascular, respiratory, sensory, and others. The rare diseases segment dominated the global market with a revenue share of more than 21.0% in 2024. According to the data published by the American Society of Gene & Cell Therapy (ASGCT), around 267 RNA therapies are currently in the pipeline for rare diseases (from preclinical through pre-registration). For non-oncology rare disorders, Duchenne’s muscular dystrophy, cystic fibrosis, and amyotrophic lateral sclerosis are the most commonly targeted indications.
The anticancer segment is anticipated to grow at the fastest CAGR during the forecast period.The initial study on cancer vaccines is largely responsible for the success of the mRNA-based COVID-19 vaccines. The Pfizer/BioNTech and Moderna COVID-19 vaccines' development was sped up by utilizing the expertise of each company in the field of cancer vaccines. Personalized vaccines are developed based on molecular structures of tumors from patients to detect genetic alterations that could give rise to neoantigens. To determine whether neoantigens will attach to T-cell receptors and elicit an immunological response, algorithms are used.
Based on modality, the RNA therapy clinical trial market has been further categorized into RNA interference, Antisense therapy, Messenger RNA, and Oligonucleotide, non-antisense, and non-RNAi.The messenger RNA segment held a major revenue share of over 35% in 2024. The COVID-19 pandemic significantly accelerated the development and use of mRNA-based vaccinations, including the COVID-19 vaccines from Pfizer-BioNTech and Moderna. Due to the efficacy of these mRNA vaccines, mRNA technology has gained attention and shown promise in the fight against infectious diseases. Moreover, there are several potential uses for mRNA treatments in a variety of illness states. They can be used to encode particular proteins that make therapeutic antibodies, activate an immunological response, or restore protein function.
On the other hand, RNA interference held a significant share of the RNA therapy clinical trial industry in 2024. RNAi has shown potential therapeutic uses for a variety of disorders. It can be used to specifically target genes linked to rare genetic abnormalities or common diseases like cancer.RNAi can also be used to inhibit viral replication by targeting viral mRNA. As a result, RNAi treatments are attracting a lot of attention and funding for a range of illness indications.
Based on phases, the RNA therapy clinical trial market has been further categorized into phase I, phase II, phase III, and phase IV. The phase II segment held a major revenue share of over 42.0% in 2024. Rising investment in R&D and an increasing number of non-industry-sponsored and industry-sponsored clinical trials in phase II are major contributing factors to the segment's growth. Phase 2 studies enable the determination of the ideal dose and dosing regimen for RNA therapies.
The phase I clinical trials segment is expected to hold a significant market share in the coming years. Regulatory bodies such as the U.S. FDA, required data from phase 1 clinical trialsto aid the advancement of RNA therapies into later-stage trials.Phase 1 trials provide critical safety data for regulatory submissions, such as Investigational New Drug (IND) applications, which are required to move on to the next stages of clinical research.
North America dominated the RNA therapy clinical trials market with a share of 36.58% in 2024. This is attributed to the early adoption of RNA therapies, robust research infrastructure, regulatory environment, and strong biotechnology and pharmaceutical industry. North America has been at the forefront of the development and early adoption of RNA therapies. Several key players in the field of RNA therapeutics are based in North America, and they have spearheaded clinical trials and advanced the translation of RNA-based therapies into the clinic. Additionally, a significant number of RNA therapeutics have previously received FDA approval, and many are currently undergoing various stages of clinical studies to show their efficacy for a range of disorders.
Asia Pacific is anticipated to experience maximum growth over the forecast period with a CAGR of 4.51%. Research and development efforts in the area of RNA therapies have rapidly increased throughout the Asia Pacific region. Academic institutions, research organizations, and biotech companies are actively involved in RNA-based research in nations including China, Japan, South Korea, and Singapore, which is resulting in a growing pipeline of possible RNA therapeutics and boosting the number of clinical studies in the area.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the RNA therapy clinical trials market
Modality
Clinical Trials Phase
Therapeutic Areas
Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers